Physician profile
Annick P Hebou
NPI 1629235759
$1,712.21
in general payments reported to CMS, 2019-2025
12 companies · $74.36 in 2025
The $74.36 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $367 · 2021: $524 · 2025: $74.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $74.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $74.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $482.21 | 2019-2025 | |
| Viiv Healthcare Company | $468.49 | 2019-2021 | |
| Abbvie INC. | $370.75 | 2019-2021 | |
| Janssen Biotech, INC. | $169.83 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $58.01 | 2019-2021 | |
| Theratechnologies INC. | $52.21 | 2019 | |
| Mylan Institutional INC. | $23.50 | 2019 | |
| Napo Pharmaceuticals INC | $20.55 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $19.54 | 2021 | |
| Novo Nordisk INC | $19.32 | 2021 | |
| Alkermes, INC. | $14.88 | 2019 | |
| Hologic Sales and Service, LLC | $12.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annick Hebou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.